Med24
metabolic-therapy 15. 10. 2026 • 2 min read • European journal of obstetrics, gynecology, and reproductive biology (PubMed)

The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials.

BACKGROUND: PCOS-related infertility is closely linked to metabolic dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve insulin resistance and promote weight loss in women with PCOS, but their direct effect on reproductive outcomes remains uncertain. OBJECTIVES: To evaluate whether GLP-1RA-based...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

The study investigated the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus metformin on pregnancy rates in women with polycystic ovary syndrome (PCOS). The research aimed to determine if GLP-1RA-based therapy improved reproductive outcomes in this population.

Key Clinical Findings

A systematic review and meta-analysis of randomized trials was conducted, encompassing data from three trials involving 252 participants. The search included PubMed, Scopus, and Web of Science from their inception to February 2026. The study focused on trials comparing GLP-1RA-based therapy, either alone or combined with metformin, to metformin monotherapy in women diagnosed with PCOS. Four reports from the three randomized trials were included in the analysis. GLP-1RA-based treatment did not significantly improve overall pregnancy rates. However, it was associated with an increase in natural pregnancy rates. The effect on in vitro fertilization (IVF) pregnancy was not significant. Trial sequential analysis supported the finding for natural pregnancy, while the evidence for overall pregnancy was underpowered.

Sponsored content

Evidence Certainty and Conclusions

The certainty of evidence was rated as moderate for natural pregnancy and low for the other outcomes. The study concluded that GLP-1 receptor agonists show preliminary signals for improving spontaneous conception in women with PCOS. However, the available evidence remains limited, and current evidence is insufficient to draw conclusions regarding IVF outcomes. Larger trials with standardized endpoints, including live birth, are needed.

Original Scientific Source
European journal of obstetrics, gynecology, and reproductive biology (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement